The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(E)-N-(4-(2-(3-bromo-4-hydroxy-5-methoxybenzylidene)hydrazinecarbonyl)phenyl)acetamide ID: ALA3394892
PubChem CID: 135613372
Max Phase: Preclinical
Molecular Formula: C17H16BrN3O4
Molecular Weight: 406.24
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: COc1cc(/C=N/NC(=O)c2ccc(NC(C)=O)cc2)cc(Br)c1O
Standard InChI: InChI=1S/C17H16BrN3O4/c1-10(22)20-13-5-3-12(4-6-13)17(24)21-19-9-11-7-14(18)16(23)15(8-11)25-2/h3-9,23H,1-2H3,(H,20,22)(H,21,24)/b19-9+
Standard InChI Key: JLSPHNGKRXLQGQ-DJKKODMXSA-N
Molfile:
RDKit 2D
25 26 0 0 0 0 0 0 0 0999 V2000
1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0031 -3.0008 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.0432 -3.5993 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3383 -1.3500 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.3383 1.3500 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
2.5972 1.5031 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5951 3.0039 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.8933 3.7570 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.8912 5.2578 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1894 6.0109 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8509 5.8560 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.1894 7.5110 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4884 8.2610 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7875 7.5110 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7875 6.0110 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4885 5.2610 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.0888 8.2588 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.3875 7.5066 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.3854 6.3066 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4279 8.1045 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
6 7 1 0
7 8 1 0
5 9 1 0
4 10 1 0
2 11 1 0
11 12 2 0
12 13 1 0
13 14 1 0
14 15 1 0
14 16 2 0
15 17 2 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 15 1 0
19 22 1 0
22 23 1 0
23 24 1 0
23 25 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 406.24Molecular Weight (Monoisotopic): 405.0324AlogP: 2.89#Rotatable Bonds: 5Polar Surface Area: 100.02Molecular Species: NEUTRALHBA: 5HBD: 3#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: 8.29CX Basic pKa: 0.92CX LogP: 2.51CX LogD: 2.46Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.53Np Likeness Score: -1.24
References 1. Miknis GF, Stevens SJ, Smith LE, Ostrov DA, Churchill ME.. (2015) Development of novel Asf1-H3/H4 inhibitors., 25 (4): [PMID:25582598 ] [10.1016/j.bmcl.2014.11.067 ] 2. Miknis, Greg F; Stevens, Sarah J; Smith, Luke E; Ostrov, David A and Churchill, Mair E A. 2015-02-15 Development of novel Asf1-H3/H4 inhibitors. [PMID:25582598 ]